-
MoT – Valuation of High-Tech Ventures, Lausanne
MoT – Valuation of High-Tech Ventures, Lausanne English (PDF) – 7 pages – 345kb
Month: August 2004
Archive
Categories
- Let’s Interview Series (54)
- News (47)
- Other Documents (12)
- Presentations (100)
- Reports and analyses (57)
- Whitepapers (4)
- Interviews with leading Life Sciences companies: Pixie Dust Technologies
- Venture Valuation/Biotechgate Announces Participation in Biotech Showcase, the J.P. Morgan 41st Annual Healthcare Conference 2024 and RESI
- Venture Valuation Strengthens its Presence in North America With Sales Team Expansion
- Interviews with leading Life Sciences companies: Rebirthel
- Life Sciences M&A Report: Half-Year 2023
Category Tags
409A valuation AI Medical Service AOT asset valuation Biotech firms Biotechgate Biotechgate Digital Partnering brain activity measuring breast cancer Cells clinical trial database Cold Ablation Robotguided Laser Osteotome cranio-maxillofacial surgery Cyrill Bätscher early digestive track cancer detection Ferring Pharmaceutical filming Fujieda Ayumi Funding future of life sciences Gergely Ivanyi German Biotech German Life Sciences GTAI Health Made in Germany Heartseed Inc. HelloPartnering in-licensing opportunities JPM San Francisco Kiyoshi Hasegawa life science database Lily MedTech Inc. medical image analysis NeU Corporation patrik frei product valuation RESI Rhine-Main-Neckar biotech SARS CoV 2 Shiho Azuma Tomohiro Tada valuation Valuation Experts XB-01 Yone Production Co Ltd
